These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6157011)

  • 1. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.
    Hommers OR; Lamers KJ; Reekers P
    J Neurol; 1980; 223(3):177-90. PubMed ID: 6157011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
    Hommes OR; Prick JJ; Lamers KJ
    Clin Neurol Neurosurg; 1975; 78(1):59-72. PubMed ID: 1157430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
    Lamers KJ; Uitdehaag BM; Hommes OR; Doesburg W; Wevers RA; von Geel WJ
    J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1334-7. PubMed ID: 2465387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic trials of multiple sclerosis and intrathecal IgG production.
    Wender M; Tokarz E; Michalowska G; Wajgt A
    Ital J Neurol Sci; 1986 Apr; 7(2):205-8. PubMed ID: 3013800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression.
    Hommes OR; Aerts F; Bahr U; Schulten HR
    J Neurol Sci; 1983 Feb; 58(2):297-303. PubMed ID: 6834081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis.
    Wajgt A; Górny M; Szczechowski L; Grzybowski G; Ochudło S
    Acta Med Pol; 1989; 30(3-4):121-8. PubMed ID: 2485126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunosuppressive treatment in multiple sclerosis].
    Oliveira TV; Gorz-Reinhardt AM; Gracia CM; Bittencourt PR
    Arq Neuropsiquiatr; 1992 Sep; 50(3):295-301. PubMed ID: 1308406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal IgG synthesis and IgG index after intensive and chronic immunosuppressive treatment of multiple sclerosis.
    Hommes OR; Lamers KJ; van Geel W
    Ann N Y Acad Sci; 1984; 436():410-7. PubMed ID: 6598019
    [No Abstract]   [Full Text] [Related]  

  • 10. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
    Likosky WH; Fireman B; Elmore R; Eno G; Gale K; Goode GB; Ikeda K; Laster J; Mosher C; Rozance J
    J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1055-60. PubMed ID: 1783915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study.
    Khatri BO; Koethe SM; McQuillen MP
    Arch Neurol; 1984 Jul; 41(7):734-8. PubMed ID: 6234867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [IgG synthesis in the cerebrospinal fluid in patients with the chronic progressive phase of multiple sclerosis treated with cyclophosphamide and ACTH].
    Wender M; Michałowska G
    Neurol Neurochir Pol; 1986; 20(6):536-41. PubMed ID: 3037408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
    Gonsette RE; Demonty L; Delmotte P
    J Neurol; 1977 Feb; 214(3):173-81. PubMed ID: 65452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cyclophosphamide changes oligoclonal immunoglobulin G spectrum in cerebrospinal fluid in slowly progressing multiple sclerosis].
    Ochudło S; Wajgt A
    Neurol Neurochir Pol; 1996; 30(1):7-16. PubMed ID: 8657352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
    Lancet; 1991 Feb; 337(8739):441-6. PubMed ID: 1671468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.
    Theys P; Gosseye-Lissoir F; Ketelaer P; Carton H
    J Neurol; 1981; 225(2):119-33. PubMed ID: 6164763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of treatment with Encorton (Polfa), Solu-Medrol and Encorton and Cyclophosphamide and Encorton on the production of immunoglobulin G in the central nervous system in multiple sclerosis].
    Ochudło S
    Wiad Lek; 1989 Dec; 41(23):1579-83. PubMed ID: 2669352
    [No Abstract]   [Full Text] [Related]  

  • 19. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoprinosine in multiple sclerosis treatment: a preliminary study.
    Mazzarello P; Rocchelli B; Poloni M; Delodovici M; Pinelli P
    Schweiz Arch Neurol Neurochir Psychiatr; 1982; 131(2):175-9. PubMed ID: 6187064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.